Machina Capital S.A.S. acquired a new stake in Guardant Health, Inc. (NASDAQ:GH – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,370 shares of the company’s stock, valued at approximately $3,098,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. ABS Investment Management LLC purchased a new stake in shares of Guardant Health in the second quarter valued at approximately $345,069,000. MCF Advisors LLC lifted its position in shares of Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after buying an additional 151 shares in the last quarter. NFSG Corp purchased a new position in shares of Guardant Health during the 3rd quarter valued at approximately $33,000. Fulcrum Asset Management LLP purchased a new position in shares of Guardant Health during the 3rd quarter valued at approximately $37,000. Finally, Root Financial Partners LLC purchased a new position in shares of Guardant Health during the 3rd quarter valued at approximately $48,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
Guardant Health News Summary
Investors following GH have been watching these news items:
- Positive Sentiment: Stifel Nicolaus reiterated its Buy rating on GH, signaling continued analyst confidence. Article: Stifel Nicolaus Remains a Buy
- Neutral Sentiment: Piper Sandler lowered its price target from $193 to $190 but maintained an Overweight rating, a modest reduction in its outlook rather than a downgrade. Article: Piper Sandler Price Target
- Negative Sentiment: TwinStrand secured another USPTO win in its patent dispute with Guardant, an unfavorable development that could increase uncertainty around the ongoing intellectual-property case. Article: TwinStrand Secures Another USPTO Win
Analyst Ratings Changes
View Our Latest Analysis on Guardant Health
Guardant Health Trading Down 0.4%
NASDAQ:GH opened at $154.78 on Thursday. The stock has a 50 day moving average of $168.99 and a two-hundred day moving average of $132.61. Guardant Health, Inc. has a 12 month low of $74.55 and a 12 month high of $191.05. The firm has a market cap of $20.94 billion, a P/E ratio of -42.06 and a beta of 1.67.
Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.46. The firm had revenue of $360.98 million during the quarter, compared to analysts’ expectations of $350.72 million. The business’s revenue was up 36.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.74) EPS. On average, research analysts forecast that Guardant Health, Inc. will post -3.08 earnings per share for the current year.
Insider Transactions at Guardant Health
In other Guardant Health news, Director Alex M. Azar II sold 826 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the transaction, the director owned 825 shares in the company, valued at approximately $144,375. This trade represents a 50.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Steve E. Krognes sold 6,674 shares of Guardant Health stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the sale, the director directly owned 7,906 shares in the company, valued at approximately $1,389,400.44. This trade represents a 45.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,155 shares of company stock valued at $9,107,025 over the last ninety days. Company insiders own 5.60% of the company’s stock.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
See Also
- Five stocks we like better than Guardant Health
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
